This is an observational study for people with myelofibrosis (MF), lower risk or higher risk myelodysplastic syndromes (MDS), Idiopathic Cytopenia of Undetermined Significance (ICUS), and acute myeloid leukemia (AML).

In this study, participants will continue with their standard of care and any medications currently prescribed, and information will be collected relating to the standard medical care they are receiving.
   
The main purposes of this study are to use the information collected to help better understand patterns for diagnosis, treatment and outcomes, including disease progression, survival, and quality of life in these patient populations, and to use results of this study to provide information to help better understand the effect different treatments have on a patient’s disease and on their quality of life.

Participation is expected to last around 8 years.